Clinical Trial Update: Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on the safety and bioactivity of AXT107 in subjects with neovascular age-related macular degeneration across Phase 1/2. The t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• AXT107

Snippet

Sponsor: AsclepiX Therapeutics, Inc. | Conditions: Neovascular Age-related Macular Degeneration | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING